Home > Newsletters > FDAnews Drug Daily Bulletin > Public Citizen Calls for Boxed Warning on Top-Selling Hypertension Drugs
FDAnews Drug Daily Bulletin
Oct. 18, 2012 | Vol. 9 No. 205
Public Citizen Calls for Boxed Warning on Top-Selling Hypertension Drugs
Public Citizen is urging the FDA to require boxed warnings on the labels of many top-selling hypertension drugs, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and Novartis’ aliskiren, to warn against their use in combination. When taken together in any combination, there is an increased risk of side effects such as kidney failure, low blood pressure and elevated potassium levels, the group said in an Oct. 4 petition.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.